Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
A look back at the most widely read science and treatment news we covered this year.
The combination regimen improved overall survival by more than 50% compared with chemotherapy.
Adding Tukysa to Kadcyla led to an improvement in progression-free survival, including for patients whose cancer had spread to the brain.
Better outcomes were achieved with combinations of experimental new drugs targeting common and rare tumour mutations.
New therapies tested delayed relapse and, in some cases, lengthened survival, for women with cervical, ovarian and endometrial cancers.
A chemotherapy-free regimen combining immunotherapy with an antibody-drug conjugate extended survival by 15 months.
Other studies focused on bladder cancer, prostate cancer and liquid biopsies.
Overall survival was 14.4 months for HR+/HER2- patients who received sacituzumab govitecan versus 11.2 months for those given chemotherapy.
Response rates ranged from 56% to 85% for several types of tumors with high HER2 expression.
The antibody-drug conjugate is now approved for patients with hormone receptor-positive/HER2-negative or triple-negative breast cancer.
Results of the SORAYA study show antibody-drug conjugate produced remissions in one-third of patients with drug-resistant ovarian cancer.
Research also showed that treatment before surgery benefits patients with HER2-low breast cancer.
Elahere, a new antibody-drug conjugate, shrank tumors in about a third of treatment-experienced patients.
Treatment-experienced people who received the antibody-drug conjugate lived three months longer than those who got more chemotherapy.
The antibody-drug conjugate improved progression-free and overall survival for patients with low HER2 expression on breast tumors.
A new type of treatment uses antibodies to deliver cancer-fighting drugs directly to tumors.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.